

RPG LIFE SCIENCES LIMITED

Regd. Office: RPG House, 463, Dr. Annie Besant Road, Worli, Mumbai 400 030.

(Rs. in lakhs)

STATEMENT OF STANDALONE AUDITED RESULTS FOR THE YEAR ENDED 31st MARCH, 2017					
Particulars	3 months ended			Year ended	
	31.03.2017	31.12.2016	31.03.2016	31.03.2017	31.03.2016
	Unaudited			Audited	
1. Revenue:					
(a) Revenue from Operations (Gross)	7,524	6,976	7,311	31,776	29,021
Less: Excise Duty	339	323	281	1,335	1,089
Revenue from Operations (Net)	7,185	6,653	7,030	30,441	27,932
(b) Other Income	12	11	1	59	78
Total Revenue	7,197	6,664	7,031	30,500	28,010
2. Expenses:					
(a) Cost of Materials Consumed	1,425	1,119	1,309	5,898	6,025
(b) Purchases of Stock-in-Trade	965	1,239	960	5,550	3,360
(c) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	121	(191)	(25)	(864)	(241)
(d) Employee Benefits Expense	2,100	1,971	1,822	7,753	7,413
(e) Finance Cost	109	97	25	264	249
(f) Depreciation and Amortisation Expense	345	326	251	1,178	1,015
(g) Other Expenses	2,072	2,048	2,464	9,191	9,027
Total Expenses	7,137	6,609	6,806	28,970	26,848
3. Profit before Exceptional Items and Tax	60	55	225	1,530	1,162
4. Exceptional Items [Refer Note 5]	-	-	-	738	-
5. Profit before Tax	60	55	225	2,268	1,162
6. Tax Expense					
Current Tax	6	12	27	481	224
Less Minimum Alternate Tax Credit Entitlement	(6)	(12)	(27)	(481)	(224)
Deferred Tax	81	-	-	222	-
7. Profit for the period/year	(21)	55	225	2,046	1,162
of which:					
Profit before Tax from Continuing Operations	60	55	225	1,376	839
Tax Expense (net)	-	-	-	-	-
Profit for the year from Continuing Operations	60	55	225	1,376	839
Profit before Tax from Discontinuing Operations	-	-	-	154	323
Net Gain from sale of business	-	-	-	738	-
Tax Expense (net)	-	-	-	222	-
Profit for the year from Discontinuing Operations	-	-	-	670	323
8. Earnings per Share (of Rs. 8 each) (not annualised):					
(a) Basic	(0.13)	0.33	1.36	12.37	7.03
(b) Diluted	(0.13)	0.33	1.36	12.37	7.03

Notes:
1. Standalone Statement of Assets and Liabilities

(Rs. in lakhs)

Particulars	As at	As at
	31.03.2017	31.3.2016
A EQUITY AND LIABILITIES		
1. Shareholders' Funds		
(a) Share Capital	1,323	1,323
(b) Reserves and Surplus	14,085	12,036
Sub-total - Shareholders' Funds	15,408	13,359
2. Non-Current Liabilities		
(a) Long-term Borrowings	1,616	24
(b) Deferred Tax Liabilities (Net)	222	-
(c) Other Long-term Liabilities	283	261
(d) Long-term Provisions	232	199
Sub-total - Non-Current Liabilities	2,353	484
3. Current Liabilities		
(a) Short-term Borrowings	2,401	2,196
(b) Trade Payables		
Total outstanding dues of Micro and Small Enterprises	-	-
Total outstanding dues of Creditors other than Micro and Small Enterprises	2,866	3,371
(c) Other Current Liabilities	1,491	1,017
(d) Short-term Provisions	108	96
Sub-total - Current Liabilities	6,866	6,680
TOTAL - EQUITY AND LIABILITIES	24,627	20,523
B ASSETS		
1. Non-Current Assets		
(a) Fixed Assets		
Tangible Assets	8,219	9,289
Intangible Assets	5,448	1,637
Capital Work-in-Progress	182	159
(b) Long-term Loans and Advances	1,074	719
Sub-total - Non-Current Assets	14,923	11,804
2. Current Assets		
(a) Inventories	4,578	3,902
(b) Trade Receivables	3,963	3,699
(c) Cash and Bank Balances	160	80
(d) Short-term Loans and Advances	810	980
(e) Other Current Assets	193	58
Sub-total - Current Assets	9,704	8,719
TOTAL - ASSETS	24,627	20,523

2. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at its respective meetings held on 28th April, 2017.
3. The figures for the quarter ended 31st March, 2017 are the balancing figures between the audited financial results for the year ended 31st March, 2017 and the published unaudited financial results for the nine months ended 31st December, 2016.
4. The Company is exclusively engaged in the pharmaceuticals segment.
5. Pursuant to the approval of the Board of Directors at their meeting held on May 26, 2016, the Company had entered into a Business Transfer Agreement dated May 26, 2016 with Intas Pharmaceuticals Limited for sale of Biotech Business Unit, as a going concern on a slump sale basis, at a consideration of Rs. 2,487 lakhs. The sale consideration had been received on July 6, 2016 (closing date). The gain realised from the aforesaid sale of Biotech Business Unit amounting to Rs. 738 lakhs had been disclosed as an exceptional item in the financial results. The same has been considered as discontinuing operations in accordance with Accounting Standard - 24 - "Discontinuing Operations" and the requisite information for Biotech Business Unit has been furnished hereunder;

Particulars	3 months ended			Year ended	
	31.03.2017	31.12.2016	31.03.2016	31.03.2017	31.03.2016
	Unaudited			Audited	
a) Net Sales	-	-	843	643	2,437
b) Direct Expenses	-	-	561	489	2,114
c) Profit from ordinary activities before tax	-	-	282	154	323
d) Tax Expense (net of MAT Credit Entitlement)	-	-	-	-	-
e) Net Profit from ordinary activities after tax (c-d)	-	-	282	154	323
f) Profit on sale of Biotech Business Unit	-	-	-	738	-
g) Tax Expense [net of MAT credit entitlement]	-	-	-	222	-
h) Net Profit from discontinuing operations (e+f-g)	-	-	282	670	323

Particulars	Rs. In Lakhs	
	As at 31.3.2017	As at 31.3.2016
	Audited	
A Assets	-	2,502
B Liabilities	-	739

6. Pursuant to an Asset Purchase Agreement (APA) dated July 27, 2016 for purchase of Trademarks on assignment/perpetual license basis from Sun Pharmaceutical Industries Limited (including its subsidiary, Sun Pharma Laboratories Limited), the Company has capitalised the aforesaid assets amounting to Rs. 4,273 lakhs on October 21, 2016 (closing date).
7. The Board of Directors at its meeting has recommended a normal dividend of Rs.2.80/- per share of Rs 8/- each (35 %) for the year ended 31st March, 2017.
8. Figures for the prior periods have been regrouped where necessary.

For RPG Life Sciences Limited

CT. Renganathan
Managing Director
Mumbai, 28th April, 2017